George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Will double up again , once 16.25 is passed ...
Waiting on the news
Looking good for next week. Share price strong and little free float.
Looks like off and running again.
Me too, weakness clearing now will take large chunk above bid. Back to 14p then push on hopefully
I have a feeling that next week will be EVGEN's week :-)
Come on evg...get some news out..thank you :)
Finncap 15/6/20...pre phase 2/3 Covid-19 patient trials
Forecasts and valuation.
We have increased operating expenses in FY 2021 to
reflect the delayed phasing of pre-clinical costs and completion of CMC package.
We introduce FY 2022 forecasts, with the cash runway extending into Q3 CY 2021.
We maintain our target price of 25p, which is based on an rNPV for SFX-01 in mBC only. This excludes any value attributable to other indications, such as in autism or NASH,which will be pursued through non-dilutive financing sources, or the potential value of SFX-01 as a sulforaphane delivery platform.
https://researchlibrary.finncap.com/File/View?file=c0021c92-9b4c-4987-82d5-825e28dc7824
16/7/20
Next steps and summary
Focus on the strong efficacy data in breast cancer by planning and executing a Phase IIb trial
PhaseII/III trial in ARDS patients commencing shortly - COVID-19
Reduce risk and increase probability of success by expanding breadth of clinical programmes:
Grant-funded, investigator-led clinical trials (no/smallcost to Evgen)
In indications with a strong mechanistic rationale (four collaborations announced todate in non-cancer indications)
Seek commercial partnerships based on PhaseII results
Continue to explore other opportunities to monetise our IP assets
CEO recruitment process well-advanced
http://evgen.com/wp-content/uploads/2020/07/EVG-AGM-presentation-2020-16Jul20.pdf
Good news stacking UP ......one would have thought that after 4 months, they would want a new CEO in place by the start of September which should add plenty of value and no doubt be the catalyst for a flow of positive newsflow thereafter........and every chance that Evgen could have a commercial partner waiting in the wings to advance SFX-01's undoubted potential of multiple disease targets imho...watch this space....the sp will be pushing UP past 15p plus and more to new highs in anticiapation imho....Gla ;-)
Just cooling off RSI, may dip a little and traders will trade either way positive news and holders will be rewarded. Just look at N4P was 7p then 4p placing and doom and gloom all round next thing 15p. EVG are in a good place atm and multiple news flow expected over the coming weeks. Holding up very well atm lots of intra day reversals with buyers taking opportunity.
All pure speculation on a day to day basis, hold for news and it’ll go one way or the other, in it to win it ;)
It is..but flying shortly hopefully.
Very quiet around here currently, giving good scope for LTHs to build up nicely. Plenty of upside with a small mcap, could easily add another 0 to the price in the next few months
Lol ....Cheers Nolupus, i'm sure Evgen will pull their finger out sooner or later....no news is good news as they say, and hopefully the longer we have to wait , the bigger it will be. Gl ;-)
Well done Moneymunch ,
You should get a salary from Evgen because you do a better job than their investor relations dept :-)
June 30th
Mcr Breast Centre Retweeted
Rob Clarke
@RobClarkeLab
3 months and 12 days and #breastbiology lab is reopen for research. Clinical trial research and safe working are prioritised for now so that we can work towards normality and our research goals. @MCRBreastCentre
Mcr Breast Centre Retweeted
Rob Clarke
@RobClarkeLab
·
Jun 24
We’re looking for a talented student to carry out a PhD starting this September: Understanding the role of STAT3 in therapy-resistance and metastatic progression of breast cancer (MRC CASE) at The University of Manchester on http://FindAPhD.com
SFX-01's selection for Covid-19 patient trials isn't a shot in the dark, it was selected from over 130 drug application candidates for very compelling reasons. Gla ;-)
Sulforaphane clinical trials and COVID-19
August 6, 2020
A plethora of articles have been published this year on how researchers’ favorite topics can / may / should / could / will fix COVID-19. This one was different in that relevant clinical trials were both completed and already underway before a Madness of Crowds behavioral contagion infected us:
“It is crucial to understand the most appropriate context for introducing an anti-inflammatory therapy to complement an antiviral therapy. Such therapy must control inflammation without altering the ability of the host to mount an efficient adaptive immune response against the virus.
We propose that boosting endogenous cellular defenses by targeting the cytoprotective transcription factor Nrf2 (gene name NFE2L2) will promote the resolution of COVID-19 associated inflammation and also restore redox homeostasis and facilitate tissue repair.
The isothiocyanate sulforaphane (SFN) is the most potent naturally occurring NRF2 activator, with well-documented antioxidant and anti-inflammatory effects. The high bioavailability of SFN makes it an excellent candidate for alleviating excessive anti-inflammatory responses and protecting the lungs.
Even though Nrf2 is the primary mediator, additional factors contribute to the anti-inflammatory effects of SFN. SFN inhibits NF-?B, inhibitor of NF-?B kinase subunit ß (IKKß), and STAT3.
By regulating the endogenous cytoprotective systems, Nrf2 may have a more physiological role in achieving a balance between the beneficial and adverse effects of inflammation. Nrf2 inhibits IL-6 and IL-1ß gene expression.
Antioxidant and cytoprotective effects of Nrf2 activation are long-lasting and persist for several days after inducer elimination. They are mediated by enzymes that, in contrast to small molecules, have long half-lives and are not consumed, and are instead regenerated during the reactions which they catalyze.”
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359808/ “Can Activation of Nfr2 Be a Strategy against COVID-19?”